BIOMAT Database Logo BIOMAT Database Logo

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis. 2009

Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Clinical Research Unit & Institute of Biomedicine, Center for Global Health, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza. mfacanha@yahoo.com

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide were studied in healthy controls and patients with active pulmonary tuberculosis. A case-control study of 29 controls and 30 cases attending at the Health Center, July, 2004 to December, 2005 was conducted. The body mass index was significantly reduced in cases compared to controls (p < 0.001). The intestinal paracellular transport of lactulose was significantly (p = 0.019) reduced in cases compared to controls. The transcellular transport of mannitol and the lactulose:mannitol ratio were not significantly (p = 0.0698) reduced in cases compared to controls. Low serum concentrations of rifampin, isoniazid and pyrazinamide were observed in 81% (48/59), 92% (54/59) and 28% (12/59), respectively, in all individuals. The results demonstrated a marked decrease on intestinal paracellular transport in patients with active pulmonary tuberculosis and reduced serum concentrations of rifampin and isoniazid in both groups.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008297 Male Males
D011718 Pyrazinamide A pyrazine that is used therapeutically as an antitubercular agent. Tisamid
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
August 2013, Antimicrobial agents and chemotherapy,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis.
August 2009, The American journal of tropical medicine and hygiene,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Serum pyrazinamide concentrations in patients with pulmonary tuberculosis.
April 2019, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
October 1996, The European respiratory journal,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
November 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Rifampin and isoniazid in previously untreated patients with pulmonary tuberculosis.
January 1972, The American review of respiratory disease,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
April 2006, Antimicrobial agents and chemotherapy,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
November 2013, Antimicrobial agents and chemotherapy,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
August 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Mônica C Façanha, and Argina M B Gondim, and Valéria G F Pinheiro, and Elizabeth C Barroso, and Charles A Peloquin, and Richard L Guerrant, and Aldo A M Lima
Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis.
December 2006, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
Copied contents to your clipboard!